Duopharma Biotech Bhd Stock Shares Owned By Institutions
| 7148 Stock | 1.24 0.01 0.81% |
Duopharma Biotech Bhd fundamentals help investors to digest information that contributes to Duopharma Biotech's financial success or failures. It also enables traders to predict the movement of Duopharma Stock. The fundamental analysis module provides a way to measure Duopharma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Duopharma Biotech stock.
Duopharma |
Duopharma Biotech Bhd Company Shares Owned By Institutions Analysis
Duopharma Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Duopharma Biotech Bhd are shares owned by institutions. This is 100.0% lower than that of the Healthcare sector and about the same as Pharmaceuticals (which currently averages 0.0) industry. The shares owned by institutions for all Malaysia stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Duopharma Fundamentals
| Return On Equity | 10.93 | |||
| Current Valuation | 1.78 B | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 2.12 X | |||
| Revenue | 639.17 M | |||
| EBITDA | 121.38 M | |||
| Net Income | 82.98 M | |||
| Cash And Equivalents | 31.5 M | |||
| Total Debt | 297.8 M | |||
| Cash Flow From Operations | 43.2 M | |||
| Market Capitalization | 1.56 B | |||
| Total Asset | 1.16 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 1.16 B | |||
| Last Dividend Paid | 0.095 |
About Duopharma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Duopharma Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Duopharma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Duopharma Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.